Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
The use of immune checkpoint inhibitors (ICI) in cancer patients with solid organ allografts is hampered due to potential organ rejection. Here, the authors present a case report of a patient with kidney allograft and show that treatment with the mTOR inhibitor sirolimus preserves peripheral toleran...
Guardado en:
Autores principales: | Khashayar Esfahani, Tho-Alfakar Al-Aubodah, Pamela Thebault, Réjean Lapointe, Marie Hudson, Nathalie A. Johnson, Dana Baran, Najwa Bhulaiga, Tomoko Takano, Jean-François Cailhier, Ciriaco A. Piccirillo, Wilson H. Miller |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7b6d74e8eca445f991f3a9a988480cef |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Successful Milk Oral Immunotherapy Promotes Generation of Casein-Specific CD137+ FOXP3+ Regulatory T Cells Detectable in Peripheral Blood
por: Yi Zhang, et al.
Publicado: (2021) -
Nanotechnology-Based Targeting of mTOR Signaling in Cancer
por: Yoon MS
Publicado: (2020) -
The mTOR pathway is necessary for survival of mice with short telomeres
por: Iole Ferrara-Romeo, et al.
Publicado: (2020) -
mTOR-dependent phosphorylation controls TFEB nuclear export
por: Gennaro Napolitano, et al.
Publicado: (2018) -
Activity-independent targeting of mTOR to lysosomes in primary osteoclasts
por: Andrew Wang, et al.
Publicado: (2017)